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In high-burden tuberculosis (TB) settings such as South Africa 
(SA), poor ascertainment and reporting of paediatric cases are 
wide spread,[1,2] but where TB diagnosis and reporting systems are 
functioning well, it is estimated that children <15 years of age may 
account for 15 - 20% of the TB burden.[3] In SA, which has one of 
the most severe epidemics of TB in the world,[4] children aged <15 
account for >10% of reported cases,[4] making TB the fourth leading 
cause of child mortality.[5] Despite this, relatively little information 
is available about the characteristics of paediatric TB patients, 
their barriers to care,[6] how they are diagnosed and treated, or the 
outcomes and cost of their care. Existing reports of paediatric TB care 
either provide little descriptive information on the characteristics 
of paediatric patients[7,8] or present data from children’s hospitals in 
the Western Cape Province,[9,10] a setting that probably differs from 
treatment at primary care level in other provinces.
The only published estimates of the costs of drug-susceptible 
TB (DS-TB) treatment in SA are for adults and are based either 
on estimates from guidelines[11] or data from nearly two decades 
ago (2000 - 2001),[12] before the advent of large-scale access to 
antiretroviral therapy (ART) for HIV. Since treatment of adults differs 
from paediatric treatment with regard to drug regimens, laboratory 
investigations, supervision and treatment monitoring, the absence 
of cost estimates for paediatric treatment is an important gap in the 
evidence base.
Objectives
To provide evidence for TB programme planning and budgeting, we 
describe paediatric TB treatment with regard to patient characteristics, 
contacts, types of disease, treatment outcomes and treatment costs at 
three primary healthcare clinics (PHCs) in Johannesburg, SA. Actual 
costs incurred at clinics are compared with costs expected from 
national treatment guidelines.
Methods
Study sites
The study was conducted at three PHCs in the Johannesburg 
Metropolitan Municipality, SA. The study sites all serve urban 
informal settlements (townships) on the edge of Johannesburg. 
While the clinics were selected as a convenience sample, this region 
is typical of other densely populated, periurban informal settlements 
surrounding major metropolitan areas in SA, and the sites are typical 
of the public sector clinics in which most TB patients access care and 
treatment. The incidence of TB is known to be high in Johannesburg 
(500 cases per 100 000 in 2012).[13] Children aged <5 years and 5 - 
19 years are reported to account for 7.4% and 4.0% of all diagnosed 
cases, respectively.[14] In a previous study,[15] we observed that the 
three sites initiated a total of 63 children on TB treatment in the year-
long period from 1 April 2011 to 31 March 2012.
Care was provided according to the national TB treatment 
guidelines prevailing at the time of the study.[16] Diagnosis was 
typically done by sputum smear microscopy (acid-fast bacilli-
positive) in older children (≥8 years) and clinically in younger 
children (<8), who often cannot produce sputum samples. Samples 
were sent from the study clinics to a centralised laboratory for 
analysis, where GeneXpert MTB/RIF (Cepheid, USA) was introduced 
as standard in 2011. Treatment regimens depended on the child’s 
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age, history and smear positivity. In older children and younger 
children with a bacteriological diagnosis, the response to treatment 
was evaluated by smear microscopy after 2 or 3 months and 5 or 
7 months, depending on the regimen. Patients with extrapulmonary 
TB or a clinical diagnosis were assessed through clinical monitoring. 
A detailed description of the standard of care under these guidelines 
is provided in Table 1.
Study population
We created a retrospective cohort from a census of patients aged 
<18 years registered for TB treatment at the study sites during the 
2-year period 1 April 2011 - 31 March 2013. Children were included 
if their TB clinic card could be located on site and they initiated TB 
treatment; patients on isoniazid prophylaxis were excluded (Fig. 1). 
Follow-up for each patient extended from treatment initiation until 
the earlier of outcome date or transfer out. Data were censored on 
10 October 2013, after the last patient had reached the outcome date.
Data collection
Data were extracted from routinely maintained TB case registers and 
National Tuberculosis Control Programme TB clinic cards stored at 
each site. The data collected included clinical characteristics at the 
time of treatment initiation, TB treatment history, diagnosis method, 
treatment start date, drug regimens, number of clinic visits, type of 
treatment supervisor, laboratory monitoring tests, patient contacts 
and treatment outcomes. Baseline smear microscopy status and 
follow-up smear conversion were determined from laboratory results 
recorded at the end of the intensive phase of treatment, either on the 
TB clinic cards or in the clinic TB register.
Treatment outcomes and statistical analysis
Treatment outcomes were defined as per national TB guidelines[16] 
as cured, completed, failed, lost to follow-up, died or transferred 
out (Table 2). Baseline clinical characteristics, diagnosis method, 
smear conversion, drug regimens, contact tracing, directly observed 
treatment short-course (DOTS) supervision method and treatment 
outcomes were reported and summarised as proportions or medians 
with interquartile ranges (IQRs). All patients in the cohort were 
included in the analysis of characteristics and outcomes.
Cost data and analysis
The cost of treatment for TB disease was estimated from the 
perspective of the healthcare provider using a bottom-up micro-
costing approach,[18] starting from the time of clinic registration 
(date of arrival at the study clinic) to the earliest reported outcome. 
Since patients who transferred out had an unknown outcome, they 
were excluded from the cost estimates. For those with an outcome 
available, any treatment costs occurring before arrival at a study clinic 
or after loss to follow-up were unknown and were therefore excluded 
from our treatment cost estimates.
Average treatment costs were estimated for the sample as a whole 
and by patient outcome. We also estimated a ‘production cost’ or total 
cost per patient achieving a successful outcome (cured or completed), 
a calculation that takes into account the costs of providing care to all 
Table 1. Additional information concerning national guidelines for the diagnosis and treatment of drug-sensitive TB during the 
study period (2011 - 2013), South Africa
Diagnosis Study sites did not have access to on-site chest X-rays or procedures for the collection of non-sputum samples (e.g. 
fine-needle aspirate, gastric aspirate), but patients may have been referred to a study clinic following specialist 
diagnosis at another site. In children who were able to produce sputum, follow-up testing could be requested for 
those who were sputum smear-negative but still TB symptomatic, including chest X-ray at nearby hospitals, or liquid 
culture and/or line probe assay at the provincial National Health Laboratory Service laboratory. Patients with a 
history of previous TB treatment also provided a third sputum sample for culture and drug sensitivity testing. 
Treatment regimen Three distinct treatment regimens were recommended depending on age, history and smear positivity. Newly 
diagnosed children ≥8 years of age and younger children (<8 years) with new smear-positive TB or with severe 
forms of TB were treated with regimen 1, as in adults. This is a 6-month chemotherapy regimen consisting of R, 
H, Z and E, which is administered daily as a fixed-dose combination tablet of RHZE during an initial 2-month 
intensive phase, followed by a 4-month continuation phase of daily fixed-dose RH (2 RHZE/4 RH).[16] Retreatment 
cases were placed on regimen 1 if <8 years of age and smear-negative, or on regimen 2* if ≥8 years of age or 
<8 years and smear-positive. Regimen 2 consisted of a 3-month intensive phase with 2 months of daily RHZE 
and S injections and 1 month of HRZE only, followed by a 5-month continuation phase consisting of RH and E 
(2 RHZES/ 1 HRZE/5 HRE). New uncomplicated TB in young children (<8 years) was treated with regimen 3, 
consisting of a 2-month intensive phase containing of daily RHZ and a 4-month continuation phase of daily RH 
(2 RHZ/4 RH). Dosages for all regimens depended on body weight and were adjusted as needed during the course 
of treatment. Supplemental pyridoxine (12.5 mg/d) was recommended in malnourished children, HIV-infected 
children and pregnant adolescents. Co-trimoxazole preventive therapy was also recommended for all children with 
TB and HIV co-infection.
Treatment extensions The intensive phase could be extended by 1 month in the absence of smear conversion, in which case two additional 
sputum smears would be collected at the end of the extended intensive phase. The continuation phase could be 
extended by 1 month in the event of severe or complicated disease. If a treatment interruption occurred lasting less 
than 2 months, treatment could also be extended by the number of days that the patient did not take treatment.
Resistance The diagnosis of drug-resistant TB in young children required referral to a tertiary-level hospital for evaluation. In 
children who could produce a sputum sample, drug sensitivity testing was performed for retreatment cases prior to 
starting treatment, for individuals who failed to smear-convert at the end of the intensive phase of treatment, and 
for treatment failures. As of 2013, there was national coverage of Xpert MTB/RIF and therefore universal testing for 
rifampicin resistance in children with a bacteriological diagnosis.[3]
TB = tuberculosis; R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol; S = streptomycin.
*Regimen 2 has been phased out and is no longer recommended in current treatment guidelines.[17]
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patients, including those who failed therapy, were lost to follow-up 
or died.[19]
The cost of treatment per patient was estimated as the sum of 
variable and fixed costs per patient. To estimate variable costs, 
we identified and enumerated the resources consumed directly 
by individual patients, as recorded on the TB clinic cards. These 
resources included medication prescribed, TB monitoring tests 
(excluding diagnosis) and clinic visits. Drug and laboratory unit costs 
were obtained from public sector suppliers. A cost per clinic visit, 
reflecting the time spent by clinical personnel (nurses), was estimated 
as the total staff cost per month multiplied by the share of paediatric 
TB patients seen by the relevant personnel, and then divided by the 
number of paediatric TB visits per month. Salaries were obtained 
from government salary scales. These unit costs were multiplied 
by the quantity of resources used by each patient to obtain a total 
variable cost per patient.
For costs that could not be directly attributed to individual patients, 
we summed the annual costs of shared resources such as building space 
(e.g. hallways, lavatories, waiting and consultation rooms), personnel 
(e.g. clinic managers, security guards, administrative assistants, 
cleaners), equipment (e.g. furniture, excluding fixtures) and other 
consumables (e.g. cleaning materials, stationery). The sum of the 
annual fixed costs was then multiplied by the fraction of each shared 
resource that was used by paediatric TB patients to obtain the total 
annual fixed cost per study patient. The annual fixed cost per study 
patient was then divided by the average number of annual paediatric 
TB visits during the study period to obtain the fixed cost per study 
visit. This was then multiplied by the number of study visits made by 
each patient to derive the final fixed cost per patient.
All fixed costs and the staffing cost per patient visit were estimated 
using data from a single study clinic that was similar to the other two 
clinics in size and number of paediatric TB patients enrolled in care. 
Additional details for estimating variable and fixed costs, and the fraction 
of fixed costs attributable to paediatric TB care, are provided in Table 3.
All unit costs were standardised to 2015 SA rands (ZAR) and are 
reported in ZAR and US dollars (USD) at an average exchange rate 
of ZAR12.76/USD1.[22] When possible, 2015 unit costs were obtained; 
where necessary, older unit costs were inflated using the average year-
on-year inflation rate.
Guideline costs
For comparison purposes, we also estimated the cost of paediatric 
TB treatment if the prevailing guidelines[16] were strictly followed 
for laboratory investigations, medication consumed and visits made 
to the clinic. Assumptions made in the guideline cost estimates are 
documented in Table 4.
Sensitivity analysis
Patients who transferred in to a study site after initiating treatment 
elsewhere were excluded from costing analyses. The working life of 
equipment was also adjusted to vary from 2 to 8 years, and the chosen 
discount rate was modified to range from 0% to 8%.
Ethics approval
Ethics approval for this study was granted by the City of Johannes-
burg Health Department (protocol no. M130979) and the Human 
Research Ethics Committee (Medical) of the University of the 
Witwatersrand, Johannesburg (clearance certificate no. M130979).
Results
Baseline characteristics
During the study period, 88 cases were registered for TB treatment 
across the three facilities: 44.3% of these patients (39/88) were female, 
the median age was 4 years (IQR 1.0 - 9.5), 100% (88/88) were new 
TB cases, 92.0% (81/88) had pulmonary TB, 22.7% (20/88) were HIV 
co-infected, and 70.0% (14/20) of those with HIV were confirmed to 
be on ART (Table 5). Patients enrolled in the study were followed up 
for a median of 6.4 months (IQR 6.1 - 7.7) between registration at 
Table 2. Treatment outcomes
Outcome Definition
Cured Smear- or culture-positive at treatment initiation and smear- or culture-negative in the final month of treatment and 
on at least one occasion in the previous 30 days
Completed Completed treatment but did not meet the criteria for ‘cured’ or ‘failed’
Failed Smear- or culture-positive at treatment initiation and remained smear- or culture-positive in the continuation phase, 
or became smear- or culture-positive any time after treatment initiation, or whose drug susceptibility tests indicated 
the presence of rifampicin resistance
Lost to follow-up Missed more than 2 consecutive months of treatment
Died Died from any cause during treatment
Transferred Moved care to another facility during treatment
Children (<18 years) found in 
TB case register
N=105
Patient le not found
n=2
Received isoniazid prophylaxis
n=15
Treated for TB disease
n=88
Transfer out (no outcome)
n=8
Included in costing analysis
n=80
Fig. 1. Enrolment diagram. (TB = tuberculosis.)
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the sites and outcome date. Of the 80 patients included in the costing 
analysis, 11 transferred in (i.e. registered for treatment initiation at 
a non-study site before transferring to a study clinic) in a median of 
61 days (IQR 36 - 89).
Diagnosis
More than two-thirds of the patients (62/88, 70.5%) were diagnosed 
clinically, with X-rays being the most common diagnostic method 
(46.6%), followed by Mantoux (21.6%), smear microscopy (13.6%), 
GeneXpert MTB/RIF (5.7%), aspiration/biopsy (2.3%), culture 
(2.3%), magnetic resonance imaging (1.1%) and abdominal ultra-
sound (1.1%).
Smear conversion
Thirteen patients (14.8%) were recorded as smear-positive and 8 
(9.1%) as smear-negative at baseline, with others either receiving a 
clinical diagnosis or simply missing smear microscopy results. Of 
those with smear-positive TB, 11/13 (84.6%) had follow-up smears, 
and 7/13 (53.8%) had evidence of smear conversion by the end of the 
intensive phase of treatment in a median of 55 days (IQR 48 - 82). 
Only one individual was recorded as culture-positive at baseline, 
but there were no subsequent culture results available to determine 
whether culture conversion occurred.
Regimens
Just over half of the patients (56.8%, 50/88) were prescribed regimen 1 
in the intensive phase, and the rest were put on regimen 3. According 
to national treatment guidelines,[16] 19/50 (38.0%) of patients on 
regimen 1 should have been prescribed regimen 3, while 3/38 (7.9%) 
patients on regimen 3 should have been prescribed regimen 1. Most 
HIV-positive patients were prescribed co-trimoxazole (90.0%, 18/20), 
but only 55.0% (11/20) were prescribed supplemental pyridoxine, as 
is recommended.[23,24]
Contact tracing
Fewer than half (45.5%, 40/88) of the TB files contained a list of 
patient contacts. The TB files were not designed to collect data on 
whether contacts were screened for TB signs and symptoms, or 
whether they lived with the patient. Among all contacts identified 
(N=118), 10 (8.5%) had a record of being tested for TB and 1 started 
Table 3. Methods for estimating treatment costs
Type of cost Method for estimating cost
Variable costs (resources recorded on/estimated from TB clinic cards)
 Medication 
and laboratory 
investigations
Laboratory investigations and drug regimens were recorded in patient files; however, the exact quantity of medication 
dispensed at each clinic visit was not recorded. We therefore estimated drug dispensing using two assumptions: (i) that 
medication was dispensed at each clinic visit; and (ii) that the amount of medication dispensed was sufficient to last 
the patient until their next scheduled visit date. If the time between two consecutive visits was 2 weeks, we therefore 
assumed that 2 weeks’ worth of medication was dispensed. Drug and laboratory unit costs were obtained from public 
sector suppliers and multiplied by actual resource use for each patient.
Staffing (visits) The TB clinic cards do not record the specific staff cadre seen by patients. Since TB patients are typically seen by a 
single professional nurse who dispenses medication and sees both TB and non-TB patients, we assumed that all clinic 
visits were to a professional nurse. A uniform staffing cost per patient visit was estimated as the total staff cost per 
month multiplied by the share of paediatric TB patients seen by the TB nurse, divided by the number of paediatric TB 
visits per month. Salaries were obtained from government salary scales, averaged across all grades, including allowances 
and benefits. The actual number of visits made by each patient was then multiplied by this cost.
Fixed costs (resources used to operate clinic, not allocated to individual patients) 
 Buildings and 
utilities
Building space (hallways, lavatories, waiting and consultation rooms) was measured and an average rental cost per m2 
was estimated from local commercial property rental advertisements. The cost of utilities per m2 was estimated from 
clinic utility bills (electricity) or, if unavailable at the clinic, from our research office in Johannesburg (water, effluent, 
levies).
Equipment Furnishings and equipment (excluding fixtures) were inventoried and costs were estimated from government tender 
documents and quotes from private suppliers. Clinic equipment was assumed to have a working life of 5 years when 
purchased new, with durations of 2 - 8 years tested in sensitivity analysis.
Staffing Shared personnel (clinic managers, security guards, administrative assistants, cleaners) were estimated from 
government salary scales. Clinic staff were assumed to have worked 214 days per year, which takes into account leave 
allocations and public holidays.
Supplies Other consumables (cleaning supplies, clinic groceries, printing and stationery) were estimated from clinic purchase 
orders, most of which are summarised in annual reports issued by the City of Johannesburg Metropolitan Council, 
although a limited number of additional orders for stationery were collected when available. 
 Proportion of fixed 
costs attributable to 
paediatric TB care
For resources that were shared among all patients (clinic space, equipment, personnel, and supplies used by both TB 
and non-TB patients), the proportion attributable to paediatric TB care was estimated as the total number of annual 
paediatric TB visits divided by the total number of annual clinic visits made by all patients. For resources used only by 
TB patients, the proportion attributable to paediatric TB care was estimated as the fraction of paediatric TB patients 
seen by the TB nurse, who sees both TB and non-TB patients of all ages. 
 Depreciation and 
discount rate
Capital costs were annualised at a 5% discount rate; this was applied to clinic equipment and reflects the opportunity 
cost of funds used to acquire furnishings and equipment in the present. In South Africa in 2015, inflation was 4.6%[20] 
and the interest rate 9.75%.[21] An annual real interest rate (nominal minus inflation) of 5% was therefore judged to be 
an appropriate reflection of borrowing costs for purchasing equipment, with rates of 0 - 8% tested in sensitivity analysis.
TB = tuberculosis.
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treatment for TB disease. The median age of contacts identified was 
17 years (IQR 3 - 32); most were parents (34.7%) or siblings (32.2%), 
and the rest were other relatives (22.0%) or non-relatives (3.3%), or 
their relationship was unknown (7.6%).
Supervision
DOTS supervision type was missing for 51 children (58.0%) in the 
intensive phase and 59 (67.0%) in the continuation phase. For those 
whose supervision type was reported, family supervision was the 
most commonly reported supervision type (intensive phase 67.6%, 
continuation phase 72.4%), followed by a combination of family and 
community-based supervision (intensive phase 18.9%, continuation 
phase 20.7%), community-based supervision (intensive phase 8.1%, 
continuation phase 0.0%) and facility-based supervision (intensive 
phase 5.4%, continuation phase 6.9%).
Treatment outcomes
Overall treatment success was high (89.8%), with 13.6% (12/88) of 
patients cured and 76.1% (67/88) completing treatment. However, 
only 2/12 cured patients had laboratory evidence available in their TB 
clinic cards to independently confirm this outcome. The remainder 
of the patients were either lost to follow-up (1/88, 1.1%) or missing 
an outcome after transferring out (8/88, 9.1%).
Resource utilisation and treatment costs
From treatment initiation to outcome, patients utilised an average 
of 6.9 months of medication, 0.8 laboratory tests and 10 clinic visits.
Table 6 reports treatment costs. The mean (standard deviation (SD)) 
cost of treatment was ZAR1 815/USD142 (ZAR591/USD46) per 
patient in the sample, ZAR2 006/USD157 (ZAR223/USD18) per 
patient cured, ZAR1 787/USD140 (ZAR632/USD50) per patient who 
completed treatment, and ZAR1 820/USD143 (ZAR593/USD46) per 
patient with a successful treatment outcome. The ‘production cost’ 
per treatment success was ZAR1 838/USD144. The primary drivers 
of treatment costs were fixed costs (44.0%), outpatient visits (30.7%), 
medication (19.3%), and laboratory investigations (6.0%) (Table 6).
Sensitivity analyses
Excluding patients who transferred in increased the mean (SD) cost 
of treatment by 4% to ZAR1 883/USD148 (ZAR591/USD46) per 
patient and ZAR1 891/USD148 (ZAR559/USD44) per treatment 
success. Adjusting the working life of equipment and the discount 
rate led to little change in the estimated cost of treatment. With 
the working life of equipment set at 2 and 8 years, the average 
cost per treatment success was ZAR1 535/USD120 and ZAR1 509/
USD118, respectively, amounting to a change of just 1.02%. With 
the discount rate set at 0% and 8%, the average cost per treatment 
success varied even less, from ZAR1 513/USD119 to ZAR1 516/
USD119, respectively.
Guideline costing
In the guideline costing, the mean (SD) cost of treatment was 
ZAR2 020/USD158 (ZAR2 534/USD199) per patient who was 
cured, ZAR1 469/USD115 (ZAR1 409/USD110) per patient who 
Table 4. Details of guideline cost estimates, methods and assumptions
Type of cost Method for estimating variable costs
Laboratory 
investigations
We assumed that patients who were diagnosed clinically were followed up clinically. Since follow-up chest 
X-rays are not routinely recommended in children with uncomplicated TB, we also assumed that no follow-up 
X-rays were performed. In those with a bacteriological diagnosis, we assumed that response to treatment was 
evaluated by the collection of two sputum samples at each of 2 and 5 months for patients on regimens 1 or 3. 
For the 4 patients who were smear-positive at baseline and had  acid-fast bacilli-positive follow-up smears with 
no evidence of smear conversion, we assumed two additional smear microscopy tests and  drug sensitivity 
testing  at the end of an extended intensive phase of treatment. Since HIV treatment costs were not included, 
the cost of HIV laboratory tests was excluded. Unit costs were obtained from suppliers and multiplied by the 
estimated resource usage for each patient.
Medication Regimen 1 was prescribed to all new TB cases ≥8 years of age and younger children who were sputum smear-
positive. This was administered as a daily fixed-dose combination tablet containing RHZE (150, 75, 400 and 275 
mg) during the intensive phase and RH (150 and 75 mg or 300 and 150 mg) during the continuation phase, with 
dosing adjusted for weight. Regimen 3 was given to all patients <8 years of age with new and uncomplicated TB 
with no record of being smear-positive at treatment initiation. Since weight was only reported at baseline, dosing 
was estimated to be appropriate for baseline weight and was not modified with treatment duration. Costs related to 
HIV treatment (ART regimens, co-trimoxazole prophylaxis) were excluded, as TB clinic cards did not record when 
an HIV diagnosis was made or what ART regimen was prescribed. Medication that was not related to TB or HIV 
treatment was included if reported on the TB clinic cards (e.g. dapsone, carbamazepine, chlorphenamine maleate, 
vitamin B complex, vitamin C). Pyridoxine was also included, as this may be prescribed for other purposes such 
as malnutrition. Unit costs were obtained from suppliers and multiplied by the estimated resource usage for each 
patient.
Staffing (visits) We assumed that patients receiving facility-based directly observed treatment supervision attended the clinic five 
times per week, while patients with other forms of supervision (e.g. family or community-based supervision) 
attended once per month until their treatment outcome. We also assumed that all visits were to a professional 
nurse, and that those without a recorded supervisor were on community-based supervision. A uniform staffing 
cost per patient visit was estimated as the total staff cost per month multiplied by the share of paediatric TB 
patients seen by the TB nurse, divided by the number of paediatric TB visits per month. Salaries were obtained 
from government salary scales, averaged across all grades, including allowances and benefits. The estimated 
number of visits made by each patient was then multiplied by this cost.
TB = tuberculosis; R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol; ART = antiretroviral therapy.
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Table 5. Baseline characteristics of paediatric patients treated for TB disease
Characteristics Started TB treatment (N=88)*
Study clinic, n (%)
Clinic 1 31 (35.2)
Clinic 2 28 (31.8)
Clinic 3 29 (33.0)
Gender, n (%)
Female 39 (44.3)
Age (years), median (IQR) 4.0 (1.0 - 9.5)
Treatment history, n (%)
New patient 88 (100)
Classification of disease, n (%)
Pulmonary TB 81 (92.0)
Extrapulmonary TB 7 (8.0)
Smear status, n (%)
Positive 13 (14.8)
Negative 8 (9.1)
Missing 67 (76.1)
Culture status, n (%)
Positive 1 (1.1)
Missing 87 (98.9)
HIV status, n (%)
Positive 20 (22.7)
Negative 37 (42.0)
Missing 31 (35.2)
CD4+ count (cells/µL), median (IQR)† 220 (134 - 478)
ART, n (%)†
On ART 14/20 (70.0)
Not on ART 3/20 (15.0)
Missing 3/20 (15.0)
Diagnosis method, n (%)
X-rays 41 (46.6)
Mantoux 19 (21.6)
Smear microscopy 12 (13.6)
Xpert MTB/RIF 5 (5.7)
Culture 2 (2.3)
Aspiration/biopsy 2 (2.3)
MRI 1 (1.1)
Ultrasound 1 (1.1)
Missing 5 (5.7)
Treatment regimen, n (%)
Regimen 1 (2 RHZE/4 RH) 50 (56.8)
Regimen 2 (2 RHZES/1 HRZE/5 HRE) 0
Regimen 3 (2 RHZ/4 RH) 38 (43.2)
Treatment supervisor (intensive phase), n (%)
Family supervision 25 (28.4)
Both family and community-based supervision 7 (8.0)
Facility-based supervision 2 (2.3)
Community-based supervision 3 (3.4)
Missing 51 (58.0)
Treatment supervisor (continuation phase), n (%)
Family supervision 21 (23.9)
Both family and community-based supervision 6 (6.8)
Facility-based supervision 2 (2.3)
Missing 59 (67.0)
TB = tuberculosis; IQR = interquartile range; ART = antiretroviral therapy; MRI = magnetic resonance imaging; R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol;  
S = streptomycin.
*Excludes individuals on isoniazid prophylaxis (n=15): 7 (46.7%) female, median age 1 year (IQR 0.6 - 3.0), none reported as HIV-positive (5 HIV-negative, 10 unknown), 14 finished their 
prophylactic course and 1 lost to follow-up.
†HIV-positive patients only.
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completed treatment, and ZAR1 553/USD122 (ZAR1 620/USD127) 
per patient with a successful treatment outcome. The ‘production 
cost’ per treatment success was ZAR1 575/USD123. Primary drivers 
of treatment costs were fixed costs (44.0%), outpatient visits (30.7%), 
treatment medication (23.5%) and laboratory investigations (1.8%) 
(Table 7).
Discussion
In this study, we estimated an average provider treatment cost per 
patient of ZAR1 815/USD142 and a production cost per successful 
outcome of ZAR1 838/USD144, reflecting the high proportion 
of patients who were cured or completed treatment. This cost 
(ZAR1 815/USD142) is 17% higher than the estimated cost of 
guideline-based treatment (ZAR1 553/USD122), suggesting that 
there may be cost savings associated with closer adherence to 
national treatment guidelines. These differences were a result of both 
higher laboratory costs and more outpatient visits taking place than 
were recommended in the national guidelines.
As there have been no published estimates of the cost of paediatric 
TB treatment in SA, we compared our results with those of studies 
of adult patients. Our estimate was lower than previous SA cost 
estimates in adults. The most recent of these considered guideline 
costs[11] and estimated a provider diagnosis and treatment cost of 
USD257 (2011 USD) per adult pulmonary DS-TB patient, assuming 
adherence to national guidelines, with variable costs obtained from 
government sources and PHCs in the Cape Town Metro region and 
patient clinical characteristics from the literature. However, this 
estimate included the cost of diagnosis, which we excluded. Using 
data from 2000 to 2001, other estimates from SA have also found that 
the provider cost of adult DS-TB treatment ranges, depending on the 
model of service delivery, from a low of USD251 - 253 in a public 
non-governmental organisation partnership, to USD507 - 568 in 
public health clinics in the Western Cape, to USD654 - 744 in private 
workplace occupational health clinics (all 2001 USD).[12] While not 
directly comparable in terms of year or methods, these estimates all 
suggest that paediatric treatment as provided by PHCs in 2011 - 2013 
was less expensive than adult treatment.
While the treatment outcomes we observed were very good, 
our cohort did not identify any retreatment cases or patients with 
complicated TB, which require modified treatment regimens and 
additional laboratory investigations. Our sample size was also small, 
with just three clinics in one region of Johannesburg, potentially limiting 
our geographical generalisability. However, high rates of treatment 
success have been reported in other SA paediatric DS-TB cohorts, 
although studies are limited in number. Using data from a DS-TB 
treatment register in the Western Cape, treatment success rates of 80% 
have been reported, with higher rates of treatment discontinuation and 
missing outcomes in children and adolescents with HIV.[25] A small 
cohort drawn from three provinces in 2009 showed slightly higher 
rates of treatment success (88%, 65/74) in children <8 years of age. [7] 
A record review of children (aged 0 - 15 years) living in periurban 
communities found that treatment success was good (79%, 65/82 in 
2008 - 2011) among patients receiving supervised home visits from 
trained community caregivers or nurses, but clinic-based treatment 
showed relatively low rates of success (54%, 52/97 in 2005 - 2008) and 
high rates of loss to follow-up (38%).[8] In comparison, older studies 
(2003 - 2005) of hospital-based treatment in Cape Town reported 
treatment success of 71% (97/137) in HIV-infected children (aged 0 - 
11 years),[9] and higher mortality in young children (9%, 31/334, age 
<3 years) than older children (4%, 10/262, age 4 - 13 years), although 
treatment outcomes were not reported separately from patients who 
tested positive for drug resistance (11%).[10]
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We also determined that one-third of prescribed regimens in our 
study (33%, 29/88) did not appear to follow national treatment 
guidelines. While lower rates of inappropriate regimens in children 
<8 years of age (11%) have been reported in other studies from 
SA,[7] the use of inappropriate regimens is known to be a relatively 
widespread problem[26] and can contribute to both treatment failure 
and the development of drug resistance.[27] A systematic review has 
found that inadequate knowledge of national treatment guidelines 
among healthcare workers is also relatively common, although the 
review did not include any literature from SA.[28] Other problems 
with record keeping were also evident, as most of those who were 
reported as cured were missing the laboratory evidence needed to 
confirm this outcome. This issue has been noted in the treatment 
records of adult TB patients,[15] and suggests that careful staff 
training and performance monitoring are needed. We also observed 
limited contact tracing, which is of added concern because data 
from Soweto, Johannesburg, have shown high rates of undiagnosed 
TB and HIV in the household contacts and caregivers of children 
with TB.[29]
Study limitations
This study has several limitations, some of which are common 
to retrospective cohort studies. Our results depended on the 
completeness and accuracy of routinely collected data on TB clinic 
cards, which may vary across clinics. Fixed costs may also vary 
across clinics, yet we based these estimates on data from a single 
study clinic. The volume of medication dispensed needed to be 
estimated based on clinic visits, as this was not recorded directly 
in patient files. The cadre of staff seen by patients and the length 
of each visit were not recorded, so we assumed that all visits were 
made to a professional nurse, as clinic managers reported that this 
was the standard practice. Only 66.7% (14/21) of patients with a 
bacteriological diagnosis had any evidence of follow-up laboratory 
investigations, suggesting that some laboratory tests may be missing. 
The 11 patients who transferred in were missing information on 
resources consumed prior to transfer, reducing our cost estimates 
for these select patients. Sensitivity tests indicate that their exclusion 
led to a slight increase in average treatment costs. Finally, national 
guidelines have been updated since this cohort was in care, although 
many of the most important updates relate to diagnostic algorithms 
rather than treatment.
Conclusions
We found that most children initiating paediatric TB treatment in 
three typical public sector clinics in Johannesburg had successful 
treatment outcomes, but there was substantial variation between 
the services actually delivered and those called for by the national 
guidelines for paediatric TB treatment. In this study, we report the 
first known estimates of paediatric DS-TB treatment costs in SA and 
demonstrate the potential cost savings of closer adherence to national 
treatment guidelines. This information provides a starting point for 
improving management of paediatric TB and planning for future 
resource needs.
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